
UNITY Biotechnology, a US firm since 2011, develops treatments for osteoarthritis, eye, and lung diseases.
UNITY Biotechnology, founded in 2011, is dedicated to developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging. The company's core mission is to alleviate the economic, personal, and societal burdens caused by age-related diseases such as osteoarthritis, ophthalmology, and pulmonary conditions. By focusing on these areas, UNITY aims to improve the quality of life for aging populations and reduce healthcare costs.
Notable figures affiliated with UNITY Biotechnology include prominent scientists and industry leaders who contribute to its innovative approach. The company has garnered significant investment from leading venture capital firms, underscoring its potential impact. Key achievements include advancing several promising therapeutic candidates through clinical trials. UNITY's work has positioned it at the forefront of biotechnology, with the potential to transform the treatment landscape for age-related diseases.

United Therapeutics

Retro Biosciences
retro.bio

Harmony Biosciences

AgeX Therapeutics

Denali Therapeutics

Longeveron
longeveron.com
Lung Biotechnology
unither.com

Rejuveron Life Sciences
rejuveron.com

Juvenescence
juvlabs.com

Brii Biosciences
briibio.com

Aurion Biotech
aurionbiotech.com

Gerostate Alpha

Cogent Biosciences
cogentbio.com

BioHealthonomics

Stealth BioTherapeutics
stealthbt.com
Companies similar to Unity Biotechnology include United Therapeutics, Retro Biosciences, Harmony Biosciences and AgeX Therapeutics.
Unity Biotechnology was founded in 2009.
Unity Biotechnology's headquarters is located in South San Francisco, CA, US.
Unity Biotechnology's most recent funding round was for $4.3M (USD) in November 2023.
As of Nov 10, 2023, Unity Biotechnology has raised a total of $294.9M (USD).
Unity Biotechnology has 70 employees as of Feb 6, 2024.